Michael R Dean

US Patent:

6552181, Apr 22, 2003

Filed:

May 16, 1997

Appl. No.:

08/857636

Inventors:

Michael Carlton Dean - Frederick MD
Heidi Eve Hahn - Washington DC
Carol Wicking - Auchenflower, AU
Jeffrey Christiansen - Yeronga, AU
Peter G Zaphiropoulos - Tullinge, SE
Mae R. Gailani - Guilford CT
Susan Mary Shanley - Norman Park, AU
Abirami Chidambaram - Frederick MD
Igor Vorechovsky - Huddinge, SE
Erika Holmberg-Lindstrom - Solna, SE
Anne Birgitte Unden - Huddinge, SE
Susan Alana Gillies - Newfarm, AU
Kylie Negus - Queenslopes, AU
Ian Mcleod Smyth - Fig Tree Pocket, AU
Carol Leah Pressman - Houston TX
David J. Leffell - New Haven CT
Bernard Gerrard - Frederick MD
Alisa Miriam Goldstein - Rockville MD
Brandon Wainwright - Bardon, AU
Rune Carl-Magnus Toftgard - Skarholmen, SE
Georgia Chenevix-Trench - Toowong, AU
Allen E. Bale - Northford CT

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07H 2104

US Classification:

536 2431, 536 235, 4353201

Abstract:

This invention provides for a tumor suppressor gene inactivation of which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a homologue of the (ptc) gene.

US Patent:

6600030, Jul 29, 2003

Filed:

Aug 10, 1998

Appl. No.:

09/131827

Inventors:

Michael Dean - Frederick MD
Stephen J. OBrien - Frederick MD
Michael Smith - Jefferson MD
Mary Carrington - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 3817

US Classification:

536 235, 4242081, 435 6, 435 691, 435 701, 435 711, 435 712, 435325, 435243, 4352523, 4353201, 435975, 514 44, 530350, 536 231, 536 243, 536 2431, 536 2433

Abstract:

The present invention relates to a CCR2 deletion mutant, designated âCCR2-64I. â CCR2 is a CâC chemokine receptor and has been implicated as a co-receptor for HIV-1. It has been discovered that the presence of the CCR2-64I allele correlates with a postponement of AIDS outcomes, and that infected individuals who have the CCR2-64I allele are at a reduced risk for progression from HIV-1 infection to the development of clinical AIDS and death. Isolated nucleic acid molecule encoding CCR2-64I and the establishment of cell lines that express CCR2-64I provides valuable tools for continuing research on HIV infection. Diagnostic methods for analysis of the allelic frequency of CCR2 wild-type and 64I genes are provided. In addition, antibodies which bind to CCR2-64I, CCR2-64I variants, and CCR2 binding agents represent potential anti-HIV agents.

US Patent:

6713300, Mar 30, 2004

Filed:

Feb 27, 1998

Appl. No.:

09/032438

Inventors:

Rando Allikmets - Frederick MD
Kent L. Anderson - Houston TX
Michael Dean - Frederick MD
Mark Leppert - Salt Lake City UT
Richard A. Lewis - Houston TX
Yixin Li - Houston TX
James R. Lupski - Houston TX
Jeremy Nathans - Baltimore MD
Amir Rattner - Baltimore MD
Noah F. Shroyer - Houston TX
Nanda Singh - Salt Lake City UT
Philip Smallwood - Woodbine MD
Hui Sun - Baltimore MD

Assignee:

University of Utah Research Foundation - Salt Lake City UT
Baylor College of Medicine - Houston TX
Johns Hopkins University - Baltimore MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 1500

US Classification:

435325, 435 691, 4353201, 435455, 536 231, 536 235

Abstract:

The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.

US Patent:

6867017, Mar 15, 2005

Filed:

Oct 21, 1999

Appl. No.:

09/422840

Inventors:

Michael Dean - Frederick MD, US
Rando Allikmets - Monroe NY, US
Amy Ann Hutchinson - Fort Lee NJ, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N015/12
C12N015/63
C12N005/00
C07K014/00
C07H021/04

US Classification:

435 691, 4353201, 435325, 435 6, 530350, 536 235

Abstract:

Disclosed is a novel ATP-binding cassette gene (ABC7), polypeptide and methods of detecting mutations therein. Further, the disclosure provides methods of detecting ABC7 associated disease and treatments thereof. In particular, the disclosure provides methods of detecting X-linked Sideroblastic Anemia and Ataxia associated with a mutation in the ABC7 polypeptide.

US Patent:

6893841, May 17, 2005

Filed:

Mar 5, 2002

Appl. No.:

10/087782

Inventors:

Marie Rosier - Antony, FR
Catherine Prades - Thiais, FR
Isabelle Arnould - Chennevieres sur Marne, FR
Michael Dean - Frederick MD, US
Rando Allikmets - Cornwall-on-Hudson NY, US
Patrice Denefle - Saint Maur, FR

Assignee:

Aventis Pharma S.A. - Antony

International Classification:

C12N015/12
C12N005/10
C12P021/02
C07K014/47

US Classification:

435 691, 4353201, 435471, 4352523, 435325, 435 711, 530 235, 530351

Abstract:

The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.

US Patent:

7138493, Nov 21, 2006

Filed:

Nov 24, 1999

Appl. No.:

09/856927

Inventors:

Michael Dean - Frederick MD, US
Rando L. Allikmets - Cornwall-on-the-Hudson NY, US
Susan E. Bates - Bethesda MD, US
Antonio T. Fojo - Rockville MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07K 5/00

US Classification:

530350, 5303891, 536 231, 536 235

Abstract:

This invention provides for a novel ATP-binding cassette protein which is responsible for cytotoxin resistance. The invention also provides for methods of expressing the protein and assays for identification of inhibitors of the protein.

US Patent:

7141420, Nov 28, 2006

Filed:

Jan 10, 2003

Appl. No.:

10/340097

Inventors:

Rando Allikmets - Frederick MD, US
Kent L. Anderson - Houston TX, US
Michael Dean - Frederick MD, US
Mark Leppert - Salt Lake City UT, US
Richard A. Lewis - Houston TX, US
Yixin Li - Houston TX, US
James R. Lupski - Houston TX, US
Jeremy Nathans - Baltimore MD, US
Amir Rattner - Baltimore MD, US
Noah F. Shroyer - Houston TX, US
Nanda Singh - Salt Lake City UT, US
Philip Smallwood - Woodbine MD, US
Hui Sun - Baltimore MD, US

Assignee:

University of Utah Research Foundation - Salt Lake City UT
Baylor College of Medicine - Houston TX
John Hopkins University - Baltiomore MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 5/00
C12N 15/00
C12N 15/63
C07H 21/02
C07H 21/04
C12P 21/06
C07K 1/00

US Classification:

435325, 435 691, 4353201, 435455, 536 231, 536 235, 530350

Abstract:

The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.

US Patent:

7189511, Mar 13, 2007

Filed:

Jan 3, 2003

Appl. No.:

10/336215

Inventors:

Rando Allikmets - Frederick MD, US
Kent L. Anderson - Houston TX, US
Michael Dean - Frederick MD, US
Mark Leppert - Salt Lake City UT, US
Richard A. Lewis - Houston TX, US
Yixin Li - Houston TX, US
James R. Lupski - Houston TX, US
Jeremy Nathans - Baltimore MD, US
Amir Rattner - Baltimore MD, US
Noah F. Shroyer - Houston TX, US
Nanda Singh - Salt Lake City UT, US
Philip Smallwood - Woodbine MD, US
Hui Sun - Baltimore MD, US

Assignee:

Baylor College of Medicine - Houston TX
The United States of America as represented by the Department of Health and Human Services - Washington DC
University of Utah Research Foundation - Salt Lake City UT
John Hopkins University - Baltimore MD

International Classification:

C12Q 1/68
C12Q 1/00
C07H 21/02
C07H 21/04
C12P 21/06

US Classification:

435 6, 435 4, 435 691, 536 231, 536 235, 536 243, 536 2433

Abstract:

The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.